Hyperlipidemia Type 3 Latest Advances

Tuberoeruptive xanthomas: undiagnosed warning signs of familial dysbetalipoproteinemia in a 38-year-old male with premature ischemic heart disease.

Journal: Journal of clinical lipidology

Published: March 02, 2026

APOB to estimated APOB ratio for screening for the APOE2 genotype.

Journal: medRxiv : the preprint server for health sciences

Published: February 26, 2026

APOB to Estimated APOB Ratio for Screening for the APOE2 Genotype.

Journal: Clinical chemistry

Published: January 30, 2026

Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia.

Journal: Journal of the American College of Cardiology

Published: October 09, 2025

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Journal: Journal of the American Heart Association

Published: August 23, 2025

Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios.

Journal: Journal of clinical lipidology

Published: July 09, 2025

Genetic and Metabolic Factors of Familial Dysbetalipoproteinemia Phenotype: Insights from a Cross-Sectional Study.

Journal: International journal of molecular sciences

Published: June 18, 2025

Letter to the Editor From Xu and Lu: "Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank".

Journal: The Journal of clinical endocrinology and metabolism

Published: June 04, 2025

Dysbetalipoproteinaemia in genetically predisposed Ghanaians.

Journal: Lipids in health and disease

Published: May 26, 2025

Molecular dynamics of select missense mutations of Apolipoprotein E and their implications in Hyperlipoproteinemia type III.

Journal: Biochemistry and biophysics reports

Published: April 11, 2025

The Challenges of Diagnosing Familial Dysbetalipoproteinemia: A Case Associated With a Rare ApoE Variant.

Journal: Case reports in medicine

Published: February 20, 2025

Correction: Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.

Journal: Cell communication and signaling : CCS

Published: December 31, 2024

Hyperlipidemia Type 3 Latest Advances

Find the Latest Research About Hyperlipidemia Type 3

Tuberoeruptive xanthomas: undiagnosed warning signs of familial dysbetalipoproteinemia in a 38-year-old male with premature ischemic heart disease.

Tuberoeruptive xanthomas: undiagnosed warning signs of familial dysbetalipoproteinemia in a 38-year-old male with premature ischemic heart disease.

APOB to estimated APOB ratio for screening for the APOE2 genotype.

APOB to estimated APOB ratio for screening for the APOE2 genotype.

APOB to Estimated APOB Ratio for Screening for the APOE2 Genotype.

APOB to Estimated APOB Ratio for Screening for the APOE2 Genotype.

Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia.

Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia.

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios.

Diagnosis of familial dysbetalipoproteinemia due to APOE p.(Arg154Ser): The role of ultracentrifugation and lipid ratios.

Genetic and Metabolic Factors of Familial Dysbetalipoproteinemia Phenotype: Insights from a Cross-Sectional Study.

Genetic and Metabolic Factors of Familial Dysbetalipoproteinemia Phenotype: Insights from a Cross-Sectional Study.

Letter to the Editor From Xu and Lu: "Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank".

Letter to the Editor From Xu and Lu: "Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank".

Dysbetalipoproteinaemia in genetically predisposed Ghanaians.

Dysbetalipoproteinaemia in genetically predisposed Ghanaians.

Molecular dynamics of select missense mutations of Apolipoprotein E and their implications in Hyperlipoproteinemia type III.

Molecular dynamics of select missense mutations of Apolipoprotein E and their implications in Hyperlipoproteinemia type III.

The Challenges of Diagnosing Familial Dysbetalipoproteinemia: A Case Associated With a Rare ApoE Variant.

The Challenges of Diagnosing Familial Dysbetalipoproteinemia: A Case Associated With a Rare ApoE Variant.

Correction: Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.

Correction: Analysis of early effects of human APOE isoforms on Alzheimer's disease and type III hyperlipoproteinemia pathways using knock-in rat models with humanized APP and APOE.